Just reported
From Bristol Myers Squibb's results release of 29 अक्टूबर 2026; its quarterly report has since been filed.
Actual
$13.07B
+6.9% y/y
+0.7% q/q
Guided
—
No guide given
Actual
$1.05
-2.8% y/y
-35% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
आमदनी के हिस्से FY2025 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।
Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.
Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.
Bristol Myers Squibb researches, develops, manufactures and sells prescription medicines around the world. Its medicines treat diseases including cancer, blood disorders, immune conditions, heart disease and schizophrenia. It sells mainly to wholesalers, distributors and pharmacies, and also earns royalties and other revenue through partnerships.
Bristol Myers Squibb Co. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
The themes Bristol Myers Squibb is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$63.43+1.7%13 नव॰ बंद भाव
30 सितंबर 2026 तक के आँकड़े, 29 अक्टूबर 2026 को दाखिल 10-Q से
Bristol Myers Squibb discovers, makes and sells prescription medicines for cancer, blood disorders, immune conditions, heart disease and mental health conditions.
कंपनी का अनुमान: वित्त वर्ष 2026 के लिए $49B से $50B का राजस्व — एक साल पहले से 2.7% अधिक
Grade C+
भाव के नीचे की पट्टी हर तारीख की ग्रेड दिखाती है, जो सिर्फ़ उस समय तक सार्वजनिक दस्तावेज़ों से बनी है।
Bristol Myers Squibb Co. के ग्रेड इतिहास की 41 तिमाहियों में से 2 दिखाई जा रही हैं। बाकी 39 अक्टूबर 2016 तक जाती हैं।